Preferred Label : Anti-PD-L1 Antibody-drug Conjugate HLX43;
NCIt synonyms : Anti-PD-L1 ADC HLX43;
NCIt definition : An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1)
monoclonal antibody directed against the immunosuppressive ligand programmed cell
death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), conjugated, via a
cleavable linker, to a cytotoxic payload containing a camptothecin-based topoisomerase
I (topo I) inhibitor, with potential antineoplastic activity. Upon administration
of the anti-PD-L1 ADC HLX43, the anti-PD-L1 antibody moiety specifically targets and
binds to PD-L1 expressed on tumor cells. The linker is specifically cleaved in the
tumor microenvironment (TME), thereby delivering the toxin into PD-L1-expressing malignant
cells, while sparing the normal cells. The cytotoxic agent specifically inhibits DNA
topoisomerase I activity, causes double-strand breaks (DSBs) of DNA, and thereby inhibiting
DNA replication and resulting in tumor cell apoptosis. This inhibits the proliferation
of PD-L1-expressing tumor cells. In addition, HLX43 induces bystander killing effects,
thereby further decreasing PD-L1-expessing tumor cells. PD-L1, a transmembrane protein,
is expressed on the surface of certain immune cells and on many cancer cell types.
PD-L1 binding to PD-1, a negative regulator of the immune system on activated T-cells,
limits the expansion and survival of CD8-positive T-cells, suppresses the immune system
and results in immune evasion.;
Molecule name : HLX-43; HLX 43;
NCI Metathesaurus CUI : CL1926433;
Origin ID : C204168;
UMLS CUI : C5908037;
Semantic type(s)
- concept_is_in_subset
- has_target
